NO303542B1 - Farmas°ytisk aktive bicykliske-heterocykliske aminer - Google Patents

Farmas°ytisk aktive bicykliske-heterocykliske aminer

Info

Publication number
NO303542B1
NO303542B1 NO943655A NO943655A NO303542B1 NO 303542 B1 NO303542 B1 NO 303542B1 NO 943655 A NO943655 A NO 943655A NO 943655 A NO943655 A NO 943655A NO 303542 B1 NO303542 B1 NO 303542B1
Authority
NO
Norway
Prior art keywords
pharmaceutically active
heterocyclic amines
active bicyclic
bicyclic
xxx
Prior art date
Application number
NO943655A
Other languages
English (en)
Norwegian (no)
Other versions
NO943655L (no
NO943655D0 (no
Inventor
Donald E Ayer
Gordon L Bundy
Eric Jon Jacobsen
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO943655D0 publication Critical patent/NO943655D0/no
Publication of NO943655L publication Critical patent/NO943655L/no
Publication of NO303542B1 publication Critical patent/NO303542B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO943655A 1992-04-03 1994-09-30 Farmas°ytisk aktive bicykliske-heterocykliske aminer NO303542B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86364692A 1992-04-03 1992-04-03
PCT/US1993/002188 WO1993020078A1 (en) 1992-04-03 1993-03-16 Pharmaceutically active bicyclic-heterocyclic amines

Publications (3)

Publication Number Publication Date
NO943655D0 NO943655D0 (no) 1994-09-30
NO943655L NO943655L (no) 1994-12-05
NO303542B1 true NO303542B1 (no) 1998-07-27

Family

ID=25341481

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943655A NO303542B1 (no) 1992-04-03 1994-09-30 Farmas°ytisk aktive bicykliske-heterocykliske aminer

Country Status (21)

Country Link
EP (1) EP0633886B1 (pl)
JP (1) JPH08502721A (pl)
KR (1) KR100284473B1 (pl)
AT (1) ATE197051T1 (pl)
AU (1) AU675932B2 (pl)
CA (1) CA2130937A1 (pl)
CZ (1) CZ236494A3 (pl)
DE (1) DE69329574T2 (pl)
DK (1) DK0633886T3 (pl)
ES (1) ES2150941T3 (pl)
FI (1) FI944602A (pl)
GR (1) GR3035188T3 (pl)
HU (1) HUT70954A (pl)
LV (1) LV12794B (pl)
MX (1) MX9301847A (pl)
NO (1) NO303542B1 (pl)
PL (2) PL175347B1 (pl)
PT (1) PT633886E (pl)
RU (1) RU2103272C1 (pl)
SK (1) SK119194A3 (pl)
WO (1) WO1993020078A1 (pl)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795986A (en) * 1995-03-02 1998-08-18 Pharmacia & Upjohn Company Pyrimido 4,5-B!indoles
DK0948495T3 (da) 1996-11-19 2004-06-01 Amgen Inc Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
WO1998024453A1 (fr) * 1996-12-05 1998-06-11 Nippon Shinyaku Co., Ltd. Medicaments pour la myelopathie
SK283378B6 (sk) * 1997-01-08 2003-06-03 Pharmacia & Upjohn Company Farmaceuticky aktívne tricyklické amíny, medziprodukty na ich prípravu
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB2331988B (en) 1997-12-04 2003-04-16 Imperial College Polycyclic sulphamate inhibitors or oestrone sulphatase
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
AR020590A1 (es) 1998-06-02 2002-05-22 Cadus Pharmaceutical Corp 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CA2342855A1 (en) * 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyranoses
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
JP2003519102A (ja) 1999-12-02 2003-06-17 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ▲下１▼、ａ▲下２ａ▼およびａ▲下３▼受容体に対して特異的な化合物並びにその使用
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6610688B2 (en) 1999-12-21 2003-08-26 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
CA2415742A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
SE0003795D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
CA2468673C (en) 2001-11-30 2011-01-25 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1 and a3 receptors and uses thereof
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
WO2004092173A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
US20070185217A1 (en) * 2003-12-23 2007-08-09 Abraxis Bioscience, Inc. Propofol analogs, process for their preparation, and methods of use
JP5078350B2 (ja) * 2004-03-04 2012-11-21 キッセイ薬品工業株式会社 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
RU2007101509A (ru) 2004-06-17 2008-07-27 Уайт (Us) Способ получения антагонистов рецепторов гормона, высвобождающего гонадотропин
BRPI0512261A (pt) 2004-06-17 2008-02-26 Wyeth Corp antagonistas de receptor de hormÈnio liberador de gonadotropina
DE602005009209D1 (de) 2004-06-18 2008-10-02 Biolipox Ab Zur behandlung von entzündungen geeignete indole
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
ATE501119T1 (de) 2005-01-19 2011-03-15 Biolipox Ab Entzündungshemmende indol-derivate
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
FR2884824B1 (fr) 2005-04-20 2007-07-13 Sanofi Aventis Sa Derives de 1h-pyrimido[4,5-b]indole, leur preparation et leur application en therapeutique
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
KR100749216B1 (ko) * 2006-08-30 2007-08-13 위아 주식회사 4륜구동차량용 부변속기
MX2009004898A (es) 2006-11-09 2009-05-19 Hoffmann La Roche Derivados de indol y de benzofurano-2-carboxamida.
AR068054A1 (es) * 2007-08-08 2009-11-04 Smithkline Beecham Corp Compuestos de pirrolopirimidina
RU2437883C1 (ru) * 2007-08-17 2011-12-27 Эл Джи Лайф Сайенсиз Лтд. Соединения индола и индазола в качестве ингибитора некроза клетки
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
MX2010007661A (es) 2008-01-31 2010-08-03 Sanofi Aventis Azaindol-3-carboxamidas ciclicas, su preparacion y su uso como productos farmaceuticos.
TW200938201A (en) * 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
AU2009314544C1 (en) * 2008-11-11 2015-11-12 Xcovery Holding Company Llc PI3K/mTOR kinase inhibitors
EP2624696B1 (en) 2010-10-06 2016-12-21 Glaxosmithkline LLC Benzimidazole derivatives as pi3 kinase inhibitors
UY33883A (es) * 2011-01-31 2012-08-31 Novartis Ag Novedosos derivados heterocíclicos
CN103562208B (zh) 2011-03-15 2016-08-31 默沙东公司 三环促旋酶抑制剂
WO2013061305A1 (en) 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
ES2733946T3 (es) 2012-01-27 2019-12-03 Univ Montreal Derivados de pirimido[4,5-b]indol y su uso en la expansión de células madre hematopoyéticas
MX2014015769A (es) 2012-06-29 2015-04-10 Pfizer 7h-pirrolo[2,3-d]pirimidinas 4-(amino-substituidas)novedosas como inhibidores de lrrk2.
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
SG11201607586UA (en) 2014-03-13 2016-10-28 Agency Science Tech & Res Fused pyrimidine-based hydroxamate derivatives
CA2962329C (en) 2014-09-22 2023-12-19 Yu-Sheng Chao Heterocyclic compounds and use thereof
JP6954844B2 (ja) 2015-06-05 2021-10-27 エマ−ケベック 造血幹細胞を培養するため及び／又は造血幹細胞を前駆体へ分化させるための方法及びその使用
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2018039310A1 (en) 2016-08-24 2018-03-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US20200399268A1 (en) * 2018-02-16 2020-12-24 UCB Biopharma SRL Pharmaceutical 6,5 Heterobicyclic Ring Derivatives
WO2021247841A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Purines and methods of their use
US20230234943A1 (en) * 2020-06-26 2023-07-27 Tempest Therapeutics, Inc. Trex1 inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864145A (en) * 1959-06-02 1961-03-29 Thomae Gmbh Dr K Novel purines and a process for their manufacture
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
DE69027862T2 (de) * 1989-09-19 1997-03-06 Teijin Ltd., Osaka Pyrrolo[2,3-d]pyrimidinderivate, verfahren zur herstellung und arzneimittelzusammensetzungen die diese enthalten

Also Published As

Publication number Publication date
LV12794A (en) 2002-02-20
PL175327B1 (pl) 1998-12-31
HUT70954A (en) 1995-11-28
WO1993020078A1 (en) 1993-10-14
PT633886E (pt) 2001-03-30
CZ236494A3 (en) 1994-12-15
KR950700912A (ko) 1995-02-20
RU2103272C1 (ru) 1998-01-27
KR100284473B1 (ko) 2001-04-02
DE69329574T2 (de) 2001-05-31
NO943655L (no) 1994-12-05
ES2150941T3 (es) 2000-12-16
RU94042466A (ru) 1996-07-20
JPH08502721A (ja) 1996-03-26
MX9301847A (es) 1993-10-01
SK119194A3 (en) 1995-05-10
AU675932B2 (en) 1997-02-27
ATE197051T1 (de) 2000-11-15
LV12794B (en) 2002-06-20
EP0633886B1 (en) 2000-10-18
AU3917493A (en) 1993-11-08
FI944602A0 (fi) 1994-10-03
HU9402829D0 (en) 1995-02-28
PL175347B1 (pl) 1998-12-31
CA2130937A1 (en) 1993-10-14
EP0633886A1 (en) 1995-01-18
FI944602A (fi) 1994-10-03
NO943655D0 (no) 1994-09-30
GR3035188T3 (en) 2001-04-30
DE69329574D1 (de) 2000-11-23
DK0633886T3 (da) 2000-12-18

Similar Documents

Publication Publication Date Title
NO303542B1 (no) Farmas°ytisk aktive bicykliske-heterocykliske aminer
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
LU92166I2 (fr) Glycopyrronium ou un de ses sels
BG101118A (en) Therapeutical compounds
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
EP1428821A8 (en) Piperidin-4-yl amines with analgesic effect
BR9806157A (pt) Composições farmacêuticas de descarboetoxiloratadina anidras, não higroscópicas e sem lactose
CA2198706A1 (en) Methods for the treatment of inflammatory joint disease
EP0260305A4 (en) CHINOLINYL ETHER TETRAZOLE AS A MEDIUM FOR TREATING HYPER-SENSITIVE DISEASES.
BR9903737A (pt) Carbamatos em c-11 de macrólidos antibacterianos
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
HK1067298A1 (zh) 應用於治療皮膚和/或粘膜損傷的體表應用的藥物組合物；組合物在治療皮膚和/或粘膜損傷中的用途和化合物在治療皮膚和/或粘膜損傷中的用途
SE9900833D0 (sv) Novel combination
CA2427814A1 (en) A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
BR0115883A (pt) Derivados de ácido amino-furan-2-il-acético e ácido amino-tien-2-il-acético substituìdos e seu emprego para o tratamento de cefaléia ou dor
SE9900834D0 (sv) Novel combination
DE69103773D1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
MY130725A (en) Composition and method for treating allergic diseases
CA2404210A1 (en) Pharmaceutical gel composition
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
BR9005081A (pt) Composicao farmaceutica e veterinaria e processo para o tratamento ou prevencao de helmintiase
DE69731620D1 (de) Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl) (1,4)diazepan-1-yl)-2-(aryl)butyl)benzamide zur behandlung von allergischen krankheiten